The hype surrounding Acomplia the new drug to be launched soon is not just because it is a weight loss drug but also because the drug is likely to alos gain approval as an anti smoking drug too. Acomplia is a new class of drug that functions by slowing the CB1 receptor which is located in the EndoCannabinoid System (EC System) that is found in the brain.

The EC System is mainly there to control the human body's consumption of food but it appears that it is also responsible for tobacco and nicotine dependence too. Research shows that excessive smoking actually over stimulates the EC system which causes an imbalance. The way Acomplia works is by stopping the  CB1 receptor and this restores the balance back to the EndoCannabinoid System that produces a lesser reliance on tobacco.

In research trials at the University of Cincinnati it was found that Acomplia had more or less doubled the chances of patients giving up smoking. A common complaint of smokers is that they put on weight when they give up smoking. In the same research it was fond that this weight gain was considerably reduced too, in fact by almost eighty percent. The double effect of Acomplia could make it the perfect drug for the person who wants to quit smoking.

The statistics show that even though the results were better on those who were trying to lose weight compared to those who took the drug for giving up smoking, it still nevertheless has a significant and worthwhile effect on the quitting rates of smokers.